# Botulinum Toxin type A

## Botox 100 Unit/Vial

| TAH Drug Code      | [IBOT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBOT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For the treatment of strabismus & blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients >= 12 years. Treatment of spasmodic torticollis (cervical dystonia) in adults. Treatment of dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients >= 2 years. Treatment of primary hyperhidrosis of the axilla. Treatment of glabellar lines associated with corrugator &/or procerus muscle activity. Management of focal spasticity, including treatment of upper limb spasticity associated with stroke in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Strabismus: Intramuscular. Vertical muscles and for horizontal strabismus of < 20 prism diopters: 1.25-2.5 units in any one muscle. Horizontal strabismus of 20-50 prism diopters: 2.5-5 units in any one muscle. Persistent VI nerve palsy of >= 1 month: 1.25-2.5 units in the medial rectus muscle. Maximum: 25 units as single injection for any one muscle. Blepharospasm: Intramuscular. Initially 1.25-2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pretarsal orbicularis oculi of the lower lid. Maximum cumulative dose: 200 units in 2-month period. VII nerve disorders: Patients with hemifacial spasm or VII nerve disorder should be treated as for unilateral blepharospasm. Maximum cumulative dose: 200 units in 2-month period. Spastic torticollis (Cervical dystonia): Intramuscular. Individualised dosing. Maximum cumulative dose:<= 360 units in 2-month period and administer no more frequently than every 2 months. Spasticity (due to juvenile cerebral palsy) in patients 2 years of age and older: Intramuscular. 4 units/kg into each of 2 sites in the medial and lateral heads of the gastrocnemius muscle of the affected lower limb(s). Maximum total dose in 30-day period: 200 units. Primary axillary hyperhidrosis: 50 unit intradermally to each axilla evenly distributed in multiple sites about 1-2 cm apart. Administer no more frequently than every 2 months. Reduction of glabellar lines: Intramuscular. Inject 4 units into each of 5 sites, two in each corrugator muscle and one in the procerus muscle for a total dose of 20 units. Reduction of lateral canthus lines (Crow's feet): Intramuscular. Inject 2-6 units into 3 injection sites per side (6 total injection points) in the lateral orbicularis oculi muscle. Reduction of forehead lines: Intramuscular. Inject 2 to 6 units into each of four sites in the frontalis muscle every 1 to 2 cm along either side of forehead crease and 2 to 3 cm above eyebrows for total dose of 8-24 units. Stroke-related upper limb spasticity: Intramuscular. Inject into selected muscles (typically the flexor muscles of the elbow, wrist & fingers), start with lowest dose, maximum: 50 units/site. Maximum dose per treatment session: 360 units. May be repeated when the effects have lessened, but generally no sooner than 12 weeks after the previous injection. Lower limb spasticity: Intramuscular. Total dose of 300 to 400 units IM divided among 5 muscles (gastrocnemius, soleus, posterior tibial, flexor pollicis longus and flexor digitorum longus). May be repeated when the effects have lessened, but generally no sooner than 12 weeks after the previous injection. Chronic migraine: Intramuscular. Total dose of 155 units as 5 units into each of 31 sites divided across 7 specific head/neck muscle areas. Usual retreatment every 12 weeks. Bladder dysfunction: Intradetrusor. Detrusor overactivity associated with neurologic condition: Total dose of 100 units/treatment initially, may increase to the maximum: 200 units/treatment, if necessary. Overactive bladder: Total dose of 100 units administered as twenty 10 units injections into the detrusor muscle; injections should be spaced approximately 1 cm apart. Median time to retreatment is approximately 24 weeks, but should be no sooner than 12 weeks. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Contraindications  | Myasthenia gravis or Eaton Lambert syndrome, infection at inj site.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Localized pain, tenderness &/or bruising, local weakness, ptosis, vertical deviation, irritation/tearing. Rarely, skin rash (including erythema multiforme, urticaria & psoriasiform eruption), pruritus, allergic reactions, dysphagia, pneumonia. Dermatologic: Injection site reaction (cervical dystonia, 5% to 22%; glabellar lines, 3% ) Gastrointestinal: Xerostomia (cervical dystonia, 13% to 39% ) Musculoskeletal: Muscle weakness (cervical dystonia, 11% to 56% ) Neurologic: Difficulty speaking (cervical dystonia, 6% to 28% ), Headache (9% to 11% ) Ophthalmic: Disorder of eye (cervical dystonia, 6% to 17% ) Respiratory: Nasopharyngitis (glabellar lines, 10% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Dysport 500 Unit/Vial

##### 臨採

| TAH Drug Code      | [IDYS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IDYS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Symptomatic relief of blepharospasm, hemifacial spasm and associated focal dystonias. Reduction of the signs and symptoms of spasmodic torticolis (cervical dystonia). Treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients >=2 yr.                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Blepharospasm 1.25 ~ 2.5 units into the medial & lateral orbicularis oculi of the upper lid & into lateral orbicularis oculi of he lower lid. Maximum 100 units every 12 weeks. Hemifacial spasm, spasmodic torticolis Individulised dosage. Paediatric cerebral palsy Administer into each of 2 sites in the medial and lateral heads of the affected gastrocnemius muscle. In hemiplegia : total dose of 4 units/kg in the affected limb. In diplegia : total dose of 6 units / kg body wt divided beween the affected lims.                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Myasthenia gravis or Eaton Lambert syndrome, infection at inj site.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Localized pain, tenderness or bruising, local weakness, ptosis, vertical deviation, irritation or tearing. Rarely, skin rash (including erythema multiforme, urticaria and psoriasiform eruption), pruritus, allergic reactions, dysphagia, pneumonia. Dermatologic: Injection site reaction (cervical dystonia, 5% to 22%; glabellar lines, 3%) Gastrointestinal: Xerostomia (cervical dystonia, 13% to 39%) Musculoskeletal: Muscle weakness (cervical dystonia, 11% to 56%) Neurologic: Difficulty speaking (cervical dystonia, 6% to 28%), Headache (9% to 11%) Ophthalmic: Disorder of eye (cervical dystonia, 6% to 17%) Respiratory: Nasopharyngitis (glabellar lines, 10%) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

